Heron Therapeutics earnings were -$34.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest HRTX earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$5.5M, down 32.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, HRTX reported annual earnings of -$20.2M, with 48.7% growth. The next HRTX earnings date is Nov 3, 2026.
What were Heron Therapeutics's earnings last quarter?
On HRTX's earnings call on Aug 10, 2026, Heron Therapeutics (NASDAQ: HRTX) reported Q2 2026 earnings per share (EPS) of -$0.03, up 50% year over year. Total HRTX earnings for the quarter were -$5.49 million. In the same quarter last year, Heron Therapeutics's earnings per share (EPS) was -$0.02.
The next HRTX earnings call is Nov 3, 2026. Add HRTX to your watchlist to be reminded of Heron Therapeutics's next earnings date.
Is Heron Therapeutics profitable or losing money?
As of the last Heron Therapeutics earnings report, Heron Therapeutics is currently losing money. Heron Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$34.05 million, a 3,557.25% increase year over year.
What was HRTX's earnings growth in the past year?
As of Heron Therapeutics's earnings date in Aug 10, 2026, Heron Therapeutics's earnings has grown year over year. HRTX earnings in the past year totalled -$34.05 million.
What are Heron Therapeutics's earnings expectations?
The current EPS estimate for Heron Therapeutics's earnings report in Nov 3, 2026 is -$0.03.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.